New and Future Therapies in Pulmonary Arterial Hypertension

ABSTRACT

Pulmonary arterial hypertension (PAH) is defined as a mean pulmonary artery pressure greater then 25 mm Hg at rest and greater then 30 mm Hg with exercise in association with normal left heart filling pressures. However, many patients with PAH have much higher pulmonary artery pressures, which, untreated, can rapidly result in marked disability, right heart failure, and death. A myriad of recent therapeutic advances have revolutionized the treatment of PAH, significantly impacting both symptoms and survival. This article briefly discusses some of the medication classes currently approved to treat patients with PAH and reviews novel therapies in the context of recent clinical trials. Also examined here are the rationale and data available for the role of combination therapy in the treatment of PAH. The article closes with speculation on new directions in the therapeutic management of this life-threatening disease.

Pulmonary hypertension - combination therapy - angiogenesis - inflammation - cell proliferation

REFERENCES

• 1 Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.  Nature. 1976;  263 663-665
• 2 Clapp L H, Finney P, Turcato S, Tran S, Rubin L J, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.  Am J Respir Cell Mol Biol. 2002;  26 194-201
• 3 Rubin L J. Primary pulmonary hypertension.  N Engl J Med. 1997;  336 111-117
• 4 Olschewski H, Ghofrani H A, Schmehl T et al.. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group.  Ann Intern Med. 2000;  132 435-443
• 5 Olschewski H, Simonneau G, Galie N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 6 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
• 7 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 8 Zhao L, Mason N A, Morrell N W et al.. Sildenafil inhibits hypoxia-induced pulmonary hypertension.  Circulation. 2001;  104 424-428
• 9 Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.  Circulation. 2002;  105 2398-2403
• 10 Wilkins M R, Paul G A, Strange J W et al.. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.  Am J Respir Crit Care Med. 2005;  171 1292-1297
• 11 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
• 12 Stiebellehner L, Petkov V, Vonbank K et al.. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.  Chest. 2003;  123 1293-1295
• 13 Kataoka M, Satoh T, Manabe T et al.. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.  Circ J. 2005;  69 461-465
• 14 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 15 Ghofrani H A, Wiedemann R, Rose F et al.. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.  Ann Intern Med. 2002;  136 515-522
• 16 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
• 17 Tuder R M, Groves B, Badesch D B, Voelkel N F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.  Am J Pathol. 1994;  144 275-285
• 18 Tuder R M, Yeager M E, Geraci M W, Golpon H A, Voelkel N F. Severe pulmonary hypertension after the discovery of the familial PPH gene.  Eur Respir J. 2001;  17 1065-1069
• 19 Voelkel N F, Hoeper M, Maloney J, Tuder R M. Vascular endothelial growth factor in pulmonary hypertension.  Ann N Y Acad Sci. 1996;  796 186-193
• 20 Voelkel N F, Cool C, Taraseviciene-Stewart L et al.. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension.  Crit Care Med. 2002;  30(suppl 5) S251-S256
• 21 Jeffery T K, Morrell N W. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.  Prog Cardiovasc Dis. 2002;  45 173-202
• 22 Cool C D, Stewart J S, Werahera P et al.. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.  Am J Pathol. 1999;  155 411-419
• 23 Yeager M E, Halley G R, Golpon H A, Voelkel N F, Tuder R M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension.  Circ Res. 2001;  88 E2-E11
• 24 Lee S D, Shroyer K R, Markham N E, Cool C D, Voelkel N F, Tuder R M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.  J Clin Invest. 1998;  101 927-934
• 25 Voelkel N F, Cool C, Lee S D, Wright L, Geraci M W, Tuder R M. Primary pulmonary hypertension between inflammation and cancer.  Chest. 1998;  114(Suppl 3) 225S-230S
• 26 Lane K B, Machado R D, Pauciulo M W et al.. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.  Nat Genet. 2000;  26 81-84
• 27 Deng Z, Morse J H, Slager S L et al.. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.  Am J Hum Genet. 2000;  67 737-744
• 28 De Caestecker M, Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension.  Respir Res. 2001;  2 193-197
• 29 Humbert M, Deng Z, Simonneau G et al.. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.  Eur Respir J. 2002;  20 518-523
• 30 Roberts K E, McElroy J J, Wong W P et al.. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.  Eur Respir J. 2004;  24 371-374
• 31 Piek E, Heldin C H, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling.  FASEB J. 1999;  13 2105-2124
• 32 Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan B L. Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis.  Development. 1996;  122 1693-1702
• 33 Humbert M, Morrell N W, Archer S L et al.. Cellular and molecular pathobiology of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 13S-24S
• 34 Morrell N W, Yang X, Upton P D et al.. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.  Circulation. 2001;  104 790-795
• 35 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator.  Nat Med. 2000;  6 1399-1402
• 36 Nishimura T, Faul J L, Berry G J et al.. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.  Am J Respir Crit Care Med. 2002;  166 1403-1408
• 37 Kao P N. Simvastatin treatment of pulmonary hypertension: an observational case series.  Chest. 2005;  127 1446-1452
• 38 Llevadot J, Murasawa S, Kureishi Y et al.. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells.  J Clin Invest. 2001;  108 399-405
• 39 Vasa M, Fichtlscherer S, Adler K et al.. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.  Circulation. 2001;  103 2885-2890
• 40 Asahara T, Murohara T, Sullivan A et al.. Isolation of putative progenitor endothelial cells for angiogenesis.  Science. 1997;  275 964-967
• 41 Isner J M, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization.  J Clin Invest. 1999;  103 1231-1236
• 42 Takahashi T, Kalka C, Masuda H et al.. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.  Nat Med. 1999;  5 434-438
• 43 Badorff C, Brandes R P, Popp R et al.. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes.  Circulation. 2003;  107 1024-1032
• 44 Zhao Y D, Courtman D W, Deng Y, Kugathasan L, Zhang Q, Stewart D J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.  Circ Res. 2005;  96 442-450
• 45 Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs.  Tissue Eng. 2004;  10 771-779
• 46 Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension.  Eur Respir J. 2003;  22 358-363
• 47 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.  Rheumatology (Oxford). 2001;  40 453-459
• 48 Raeside D A, Chalmers G, Clelland J, Madhok R, Peacock A J. Pulmonary artery pressure variation in patients with connective tissue disease: 24 hour ambulatory pulmonary artery pressure monitoring.  Thorax. 1998;  53 857-862
• 49 Dawson J K, Goodson N G, Graham D R, Lynch M P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients.  Rheumatology (Oxford). 2000;  39 1320-1325
• 50 Cool C D, Kennedy D, Voelkel N F, Tuder R M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.  Hum Pathol. 1997;  28 434-442
• 51 Tuder R M, Groves B, Badesch D B, Voelkel N F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.  Am J Pathol. 1994;  144 275-285
• 52 Morse J H, Antohi S, Kasturi K et al.. Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome.  Scand J Immunol. 2000;  51 607-611
• 53 Humbert M, Monti G, Brenot F et al.. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.  Am J Respir Crit Care Med. 1995;  151 1628-1631
• 54 Chu J W, Kao P N, Faul J L, Doyle R L. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension.  Chest. 2002;  122 1668-1673
• 55 Mehta N J, Khan I A, Mehta R N, Sepkowitz D A. HIV-related pulmonary hypertension: analytic review of 131 cases.  Chest. 2000;  118 1133-1141
• 56 Bull T M, Cool C D, Serls A E et al.. Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8.  Eur Respir J. 2003;  22 403-407
• 57 Cool C D, Rai P R, Yeager M E et al.. Expression of human herpesvirus 8 in primary pulmonary hypertension.  N Engl J Med. 2003;  349 1113-1122
• 58 Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot J L, Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE.  Ann Rheum Dis. 1996;  55 561-562
• 59 Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus.  Lupus. 1993;  2 367-369
• 60 Groen H, Bootsma H, Postma D S, Kallenberg C G. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide.  J Rheumatol. 1993;  20 1055-1057
• 61 Goupille P, Fauchier L, Babuty D, Fauchier J P, Valat J P. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus.  J Rheumatol. 1994;  21 1976-1977
• 62 Dahl M, Chalmers A, Wade J, Calverley D, Munt B. Ten-year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy.  J Rheumatol. 1992;  19 1807-1809s
• 63 Herve P, Humbert M, Sitbon O et al.. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis.  Clin Chest Med. 2001;  22 451-458
• 64 Fuster V, Steele P M, Edwards W D, Gersh B J, McGoon M D, Frye R L. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation. 1984;  70 580-587
• 65 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med. 1992;  327 76-81
• 66 Frank H, Mlczoch J, Huber K, Schuster E, Gurtner H P, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.  Chest. 1997;  112 714-721
• 67 Christman B W, McPherson C D, Newman J H et al.. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.  N Engl J Med. 1992;  327 70-75
• 68 MacLean M R, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.  Br J Pharmacol. 2000;  131 161-168
• 69 Herve P, Launay J M, Scrobohaci M L et al.. Increased plasma serotonin in primary pulmonary hypertension.  Am J Med. 1995;  99 249-254
• 70 Eddahibi S, Humbert M, Fadel E et al.. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.  J Clin Invest. 2001;  108 1141-1150
• 71 Weir E K, Reeve H L, Huang J M et al.. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.  Circulation. 1996;  94 2216-2220
• 72 Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?.  J Lab Clin Med. 2002;  139 194-201
• 73 Wang H L. The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension.  Curr Opin Investig Drugs. 2004;  5 963-966
• 74 Barst R J, McGoon M, Torbicki A et al.. Diagnosis and differential assessment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 40S-47S
• 75 Ichinose F, Roberts Jr J D, Zapol W M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential.  Circulation. 2004;  109 3106-3111
• 76 Mehta S, Stewart D J, Langleben D, Levy R D. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension.  Circulation. 1995;  92 1539-1545
• 77 Surdacki A, Zmudka K, Bieron K, Kostka-Trabka E, Dubiel J S, Gryglewski R J. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension.  Wien Klin Wochenschr. 1994;  106 521-526
• 78 Petkov V, Mosgoeller W, Ziesche R et al.. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.  J Clin Invest. 2003;  111 1339-1346
• 79 Rubin L J, Groves B M, Reeves J T, Frosolono M, Handel F, Cato A E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.  Circulation. 1982;  66 334-338
• 80 Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).  Lancet. 1984;  1 1046-1047